Integra LifeSciences now expects its total fourth quarter revenues for 2011 to be approximately 3 percent lower than originally projected, according to a company news release.
The company lowered its revenue projection from $203 million to $202 million to reflect an inventory reduction initiatives by the company's instrument distributors, weakness outside of the United States and weaker than expected sales of its domestic extremities reconstruction products.
The company also updated 2012 revenue to increase 7 percent on a reported basis over 2011 revenues. The reduction in 2012 expected earnings reflects the lower performance in the fourth quarter of 2011, a stronger dollar compared to the Euro, international economic risk and slightly lower growth in domestic extremity product lines.
Related Articles on Orthopedic Devices:
Former Medtronic Executive Joins Baxter International
Biomet Receives FDA Clearance for Two Shoulder Products
38 Orthopedic & Spine Device Company Executive Moves
The company also updated 2012 revenue to increase 7 percent on a reported basis over 2011 revenues. The reduction in 2012 expected earnings reflects the lower performance in the fourth quarter of 2011, a stronger dollar compared to the Euro, international economic risk and slightly lower growth in domestic extremity product lines.
Related Articles on Orthopedic Devices:
Former Medtronic Executive Joins Baxter International
Biomet Receives FDA Clearance for Two Shoulder Products
38 Orthopedic & Spine Device Company Executive Moves